GABAB and GABAA receptors were examined by quantitative [3H]GABA autoradiography in postmortem human hippocampus from 6 histopathologically verified cases of dementia of the Alzheimer type (DAT) and 6 normal controls. Significant decrements in the Bma~ for both types of GABA receptors were observed in DAT hippocampus as compared to normal controls. No significant differences in Kd values were revealed. As compared to controls, DAT hippocampus exhibited fewer GABAa receptors in stratum moleculare of the dentate gyrus, stratum lacunosum-moleculare and stratum pyramidale of CA). Significant loss of GABAA receptors in DAT hippocampus was also observed in the CA) pyramidal cell region. These changes could not be correlated with differences in age nor in postmortem delay between the two groups. These findings may reflect the neuronal pathologies in CA~ region, in dentate gyrus, and in projections from the entorhinal cortex which are associated with the memory impairment in DAT. 
The pathologic hallmarks of dementia of the Alzheimer type (DAT) are most strikingly evident in the hippocampus. Abundant neurofibrillary tangles, neuritic plaque formation [7] and widespread granulovacuolar degeneration are localized in specific cell layers of the hippocampus [1]: the CA~ pyramidal fields, entorhinal cortical laminae I and IV, and the subiculum. Degeneration of these neuronal elements disrupts the multisynaptic circuitry through the hippocampus and serves to isolate the hippocampus from its association and limbic connections [9] . This functional dissociation of the hippocampus may contribute to the impaired memory formation and retrieval seen in dementia of the Alzheimer type (DAT) [20] .
?-Aminobutyric acid (GABA) is an ubiquitous inhibitory neurotransmitter of intrinsic hippocampal non-pyramidal neurons [21] . Several findings implicate the participation of GABAergic systems in DAT pathology. The presence of GAD-positive immunoreactive terminals in senile plaques suggests that these may represent remnants of degenerating GABAergic processes [22] . The findings of reduced synap-tosomal GABA uptake in hippocampus and cortex of Alzheimer brains are indicative of loss of GABAergic terminals [8] . GABA is also widely co-localized with somatostatin [19] , the markers for which are consistently reduced in DAT [18] . Cerebrospinal fluid (CSF) concentrations of GABA are notably lower in DAT patients as compared to controls [23] .
GABA exerts synaptic effects via two types of receptors [3] . In hippocampal granule or pyramidal cell somata, GABA elicits fast inhibitory postsynaptic potentials (IPSPs) by increasing chloride influx [2] . These somatic GABAergic responses are mediated by bicuculline-sensitive GABAA receptors. Within the dendritic and somatic layers of granule and pyramidal cells, GABA can also cause a bicucuilineinsensitive later-onset IPSP by opening K ÷ channels [5] . This effect of GABA can be mimicked by baclofen and involves activation of a distinct GABAB receptor.
Previously we have described losses of baclofen-sensitive GABAB receptors in the frontal cortex of persons who died with Alzheimer's disease [4] . In the present study, using quantitative autoradiography, we have compared the distribution and numbers of GABAA and GABAB receptors in the hippocampus of individuals who died with DAT and of normal controls who died without neurologic disease: The DAT patients died with respiratory complications following 6 or more years of progressive intellectual decline and illness. The control cases suffered sudden cardiac arrest or trauma. Previous drug history indicated that one DAT patient was taking haloperidol (6 mg/ day), another was taking benzodiazepines, and one of the control subjects was taking a calcium channel blocker. At autopsy, the brain was removed and halved in the sagittal plane. One half was fixed in formalin for histopathologic identification and the other half was retained at -70°C for receptor binding assays. The diagnosis of Alzheimer's disease was based on previously defined neuropathologic criteria [11] . Blocks of hippocampus from 6 normal control and 6 DAT brains were obtained, coded and stored at -70°C until use. Mean age and postmortem delay (PMD) were not significantly different between the two groups (mean control age = 55 + 18 years, mean DAT age=71__+7 years, mean control PMD=15.5+7.3 h, mean DAT PMD = 18.6 + 9.8 h, both non-significant by independent Student's t-test). The DAT brains were atrophic (weighing less than 1300 g). Silver-stained sections of DAT hippocampus exhibited more than 10 tangles and/or plaques per high-power field.
Tissue blocks were equilibrated at -20°C one day before the assay was performed. Forty-four 20-/tm-thick sections were cut at -20°C from each block. Sections were thaw-mounted onto gelatin/chrom-alum-coated slides and allowed to air-dry. Slides were given a 15-min prewash in 50 mM Tris-HCI buffer containing 2.5 mM CaCI2 (pH 7.40 at 4°C) to remove endogenous GABA, and dried under a stream of cool air. Each slide was then placed in a vial containing [3H]GABA (Amersham, 50 Ci/ mmol, Batch 35) with the above buffer and various drug displacers. For GABAB binding, 10 /tM isoguvacine (Cambridge Research Biochemicals, Cambridgeshire, U.K.) was present to block binding to GABAA-sensitive sites. This concentration of isoguvacine was determined to be optimal for blocking GABAA binding sites without affecting GABAB receptor binding. For GABAA binding, 100 ~m (+)-baclofen (kindly donated by CIBA-GEIGY Corporation, Summit, N J) was present to block binding to GABAB-sensitive sites. Non-specific [3H]GABA binding was assessed in the presence of both 100/zM (___)-baclofen and 100/tM isoguvacine, to ensure that both GABAB and GABAA binding sites were adequately blocked.
Studies of saturation binding to GABAB and GABAA receptors were conducted using the method of isotopic dilution of [3H]GABA by non-radioactive GABA to achieve a range of free GABA concentrations ranging from 6 nM to 1/IM. GABAB and GABAA receptor assays each employed 22 sections from each brain examined. This permitted l I-point saturation curves with blanks at each concentration point. The binding assay was conducted at 4°C for 45 min. After this period slides were removed individually and subjected to two quick rinses with cold buffer, followed by one rinse with 1.25% glutaraldehyde in acetone, and immediately dried. Slides were mounted in an X-ray cassette with the appropriate radioactive standards and apposed to LKB tritium-sensitive 3H-Ultrofilm for 3 weeks at 4°C. The standards employed are 14C-plastic standards that were previously calibrated against brain paste standards containing known amounts of tritium and protein [15] . Films were developed in Kodak D19, fixed and dried. Optical film densities in various regions of interest were quantified by spot densitometry relative to the known standards. The regions of interest included stratum moleculare of dentate gyrus, stratum lacunosummoleculare of CAI, stratum pyramidale of CAI and subiculum. The autoradiographic image was compared to a Cresyl violet stain of the underlying tissue section to determine the anatomic regions of interest. Bound values at each concentration of GABA in these various regions were quantified in pmol/mg protein. For both types of GABA receptors, Scatchard plots were constructed to generate Bma x and Kd values using computer-assisted linear regression. The code was broken and differences in Bmax and Kd values between control and DAT groups were analyzed for significance by independent, two-tailed Student's t-test and by Mann-Whitney U-test.
In the presence of 2.5 mM CaCI2, [3H]GABA bound to human hippocampus in a distinct laminar pattern to two populations of receptors isoguvacine-sensitive GABAA and baclofen-sensitive GABAB receptors. When both isoguvacine and baclofen were present, no specific [3H]GABA binding remained on the section. The distributions of GABAB and GABAA receptor binding to human hippocampus were most prominent in the stratum moleculare of the dentate gyrus, stratum lacunosummoleculare and stratum pyramidale of CAt. Intermediate density of [3H]GABA binding to the subiculum and dentate hilus, and negligible binding to white matter were observed (Fig. 1 ). There were roughly 3 times more GABAA than GABAB receptors in both control and DAT hippocampus.
Specific binding of [3H]GABA to both GABAB and GABAA receptor sites was saturable after 45 min at 4°C. Analysis of the Scatchard plots did not disclose consistent differences in the Kd values between controls and DATs, but did reveal striking changes between the two groups in the Bm~x of hippocampal [3H]GABA binding. Notably, GABAB receptors in the DAT group were reduced by 50-70% relative to controis in stratum moleculare of dentate gyrus, stratum lacunosum-moleculare and stratum pyramidale of CA1. Significant differences in Bm~x values of GABAA binding between DAT and controls were found only in stratum pyramidale of CAl. No sig-nificant difference in Bma x values of GABAB nor GABAA binding was seen in the subiculum (Fig. 2) .
The overlapping distribution in GABAB and GABAA receptors in human hippocampus may indicate that the targets of GABAB and GABAA innervation are similar. GABA to GABAa sites. Conversely, GABAB binding (middle) was conducted in the presence of 10/tM isoguvacine to block binding to GABAA sites. The corresponding Nissl-stained sections are shown on the bottom row. SMDG, stratum moleculare of dentate gyrus; SGDG, stratum granulosum of dentate gyrus; SML, stratum lacunosum-moleculare of CAt; SP, stratum pyramidale of CA~; SUB. subiculum; HF, hippocampal fissure; Wh, white matter; LGN, lateral geniculate nucleus. Bar = 0.5 cm.
The same local circuit GABAergic interneuron may elict postsynaptic membrane hyperpolarization via both GABAA and GABAB receptors. That there appear to be relatively more GABAA than GABAB receptors in hippocampus is also consistent with the electrophysiologic observation that GABAA-mediated mechanisms predominate in the hippocampus [5, 13] . Interestingly, the distribution of GABAA receptors in human hippocampus is in excellent agreement with that of benzodiazepine receptors [12] . Both show highest density of binding in dentate molecular layer and CAI pyramidal layer. The distribution of GABA receptors in hippocampus is also in accordance with both the topography of GAD-positive [14] and GABA-immunoreactive terminals [6] , and that of somatostatin receptors [17] . The decreased density of GABAa and GABAA receptors in stratum lacunosummoleculare and stratum pyramidale of CA 1 region in DAT hippocampal formation most likely reflects the dendritic stunting and degeneration of pyramidal cells in DAT. This hippocampal region exhibits the highest density of neuritic plaques, tangles and granulovacuolar degeneration in DAT [l, 7, 9]. The selective loss of GABAB receptors in the dentate gyrus of DAT hippocampus may reflect the observed pathology in this region. Hyman et al. [10] have noted neuritic plaque formation in the molecular layer of dentate gyrus from DAT hippocampus. These plaques may involve dystrophic axons from entorhinal cortical neurons and/or degenerating dendrites of dentate granule cells [16] . The significant decline in GABAB receptors in this region may be related to the presence of plaques in this layer. GABAa receptors in the dentate molecular layer could exist on axon terminals from entorhinal cortical neurons or on dendrites of the granule cells themselves. It is not entirely clear whether the losses in GABAB receptors in DAT reflect neurodegeneration ofentorhinal cortical or dentate granule cells. Studies in the rat suggest the latter case to be true. GABAa receptors in dentate molecular layer are selectively spared after entorhinal cortical knife-cut lesions, but are lost after colchicine-induced neurotoxicity of granule cells (Chu et al., in preparation). The decrements in GABA receptors we have observed may thus reflect and possibly contribute to the pathological findings and clinical picture of memory impairment associated with DAT.
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